TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Caplin Point Laboratories Ltd.

CAPLIPOINT on NSE · 19 Nov 2026

NIFTY 500

2,084.60 ▼ -0.03 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance

Filings

23 filings of CAPLIPOINT since February 2025.

board outcome 8, transcript 7, dividend 3, presentation 3, results 2

FiledTypeSubject
12 Nov 2026presentation
Dividend / buy-back, Results
Caplin Point Laboratories Limited has informed the Exchange about Investor Presentation
AI summary

Caplin Point Laboratories filed its board meeting outcome on 12 November 2026, enclosing unaudited standalone and consolidated results, a press release and an investor presentation for the quarter and half year ended 30 September 2026.

Standalone revenue from operations for Q2 FY27 was Rs 241.88 crore, up from Rs 175.18 crore in the year-ago quarter; half-year revenue from operations was Rs 444.83 crore versus Rs 357.75 crore.

Standalone net profit for the quarter was Rs 130.51 crore versus Rs 102.59 crore a year earlier; half-year net profit was Rs 250.89 crore versus Rs 188.48 crore.

Consolidated revenue from operations for the quarter was Rs 629.84 crore; consolidated net profit attributable to owners for the quarter was Rs 178.10 crore.

The filing notes a final dividend of Rs 4.00 per share for FY2025-26, paid on 7 October 2026, bringing the total FY2025-26 dividend to Rs 8.00 per share.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Nov 2026board outcome
Results
Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
AI summary

Board of Caplin Point Laboratories approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, meeting held November 12, 2026 (11:15 A.M. to 1:00 P.M.).

Standalone revenue from operations for Q2 FY27 was Rs 241.88 crores versus Rs 175.18 crores a year earlier; half-year revenue from operations was Rs 444.83 crores versus Rs 357.75 crores.

Standalone net profit for the quarter was Rs 130.51 crores versus Rs 102.59 crores a year earlier; half-year net profit was Rs 250.89 crores versus Rs 188.48 crores.

Basic EPS for the quarter was Rs 17.17 (face value Rs 2) versus Rs 13.50 a year earlier.

The filing also encloses a press release, an investor presentation and the limited review report; management commentary is not included in the pages provided.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Aug 2026transcriptCaplin Point Laboratories Limited has informed the Exchange about Transcript
AI summary

Caplin Point Laboratories Limited filed the transcript of its Q1 FY2026-27 earnings call, held on August 12, 2026, for the quarter ended June 30, 2026.

The filing is a cover letter under Regulation 30(6) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The transcript is hosted on the company's website, and the letter does not state any financial figures or management commentary.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Aug 2026presentation
Capex, Dividend / buy-back, Management change, Results
Caplin Point Laboratories Limited has informed the Exchange about Investor Presentation
AI summary

Caplin Point Laboratories' board on August 12, 2026 approved unaudited Q1 FY27 results (quarter ended June 30, 2026): consolidated total revenue Rs 643.9 crore (up 20.7% YoY), consolidated PAT Rs 179.1 crore (up 18.8% YoY), consolidated basic EPS Rs 23.27.

Board recommended a final dividend of Rs 4 per equity share (200%) of Rs 2 face value for FY 2025-26, subject to AGM approval; an interim dividend of Rs 4 was paid on June 8, 2026. Record date to be communicated separately.

Board approved re-appointment of Dr. Sridhar Ganesan as Managing Director for two years (Aug 25, 2026 to Aug 24, 2028) and appointment of D. Muralidharan as Whole-Time Director for two years (Aug 12, 2026 to Aug 11, 2028), subject to shareholder approval.

Board approved convening the 35th AGM on September 25, 2026 via video conferencing.

Management said the US market revenue was Rs 137 crore (up 26% YoY) and free cash reserves stood at Rs 1,502 crore, with a Rs 40 crore free cash flow after Rs 55 crore capex in the quarter.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Aug 2026dividend
Dividend / buy-back, Management change, Results
Caplin Point Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on August 12, 2026, recommended Final Dividend of Rs. 4 per equity share.
AI summary

Board meeting outcome dated August 12, 2026: unaudited standalone and consolidated results for the quarter ended June 30, 2026 approved; standalone revenue from operations Rs 202.95 crore and net profit Rs 120.38 crore for the quarter; consolidated revenue from operations Rs 610.36 crore and net profit Rs 179.09 crore.

Board recommended a final dividend of Rs 4 per equity share (200%) of Rs 2 face value for FY 2025-26, payable on or before October 24, 2026, subject to AGM approval; record date to be communicated separately.

Board approved re-appointment of Dr. Sridhar Ganesan as Managing Director for two years from August 25, 2026 to August 24, 2028, and appointment of Mr. D. Muralidharan as Whole-Time Director for two years from August 12, 2026 to August 11, 2028, both subject to shareholder approval at the AGM.

Board approved convening the 35th AGM on September 25, 2026 via video conferencing or other audio-visual means.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Aug 2026board outcome
Dividend / buy-back, Management change, Results
Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
AI summary

Board approved unaudited standalone and consolidated results for the quarter ended June 30, 2026, with a press release and investor presentation enclosed.

Standalone: revenue from operations Rs 202.95 crore (Q1 FY27) vs Rs 182.57 crore a year earlier; net profit Rs 120.38 crore vs Rs 85.89 crore; basic EPS Rs 15.84 vs Rs 11.30.

Consolidated: revenue from operations Rs 610.36 crore vs Rs 510.22 crore a year earlier; net profit attributable to owners Rs 176.91 crore vs Rs 152.80 crore; basic EPS Rs 23.27 vs Rs 20.10.

Board recommended a final dividend of Rs 4 per equity share (200%) of Rs 2 face value for FY 2025-26, payable on or before October 24, 2026, subject to AGM approval; an interim dividend of Rs 4 was already paid on June 8, 2026.

Board re-appointed Dr. Sridhar Ganesan as Managing Director for two years (Aug 25, 2026 to Aug 24, 2028) and appointed D. Muralidharan as Whole-Time Director for two years (Aug 12, 2026 to Aug 11, 2028), who also continues as CFO, both subject to shareholder approval at the AGM.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
21 May 2026transcriptCaplin Point Laboratories Limited has informed the Exchange about Transcript
AI summary

Caplin Point Laboratories Limited filed the transcript of its Q4 FY2025-26 earnings call, held on Thursday, May 14, 2026, with analysts and investors on the financial performance for the quarter and year ended March 31, 2026.

The transcript is available on the company's website at the link given in the filing.

The filing itself does not state any financial figures or management comments from the call.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 May 2026dividend
Dividend / buy-back, Results
Caplin Point Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2026, declared Interim Dividend of Rs. 4 per equity share.
AI summary

Board of Caplin Point Laboratories Limited declared an interim dividend of INR 4.00 (200%) per equity share of face value INR 2 each for FY ended March 31, 2026.

Record date for the interim dividend is May 30, 2026.

Board approved audited standalone and consolidated financial results for the year ended March 31, 2026, with press release and investor presentation enclosed.

Statutory auditor M/s Brahmayya & Co issued unmodified audit reports on the standalone and consolidated financial statements.

Board also approved amendments to the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 May 2026board outcome
Dividend / buy-back, Results
Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Board approved an interim dividend of INR 4.00 (200%) per equity share of face value INR 2 for FY ended March 31, 2026, with May 30, 2026 as record date.

Board approved audited standalone and consolidated financial results for the year ended March 31, 2026, with unmodified audit opinion from Statutory Auditors Brahmayya & Co.

Board approved amendments to the Code of Practices and Procedure for Fair Disclosure of Unpublished Price Sensitive Information.

Press release and investor presentation on annual results were enclosed with the filing.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Feb 2026transcriptCaplin Point Laboratories Limited has informed the Exchange about Transcript
AI summary

Caplin Point Laboratories Limited filed a transcript of its Q3 FY2025-26 earnings call, held on Thursday, February 5, 2026, covering the quarter and nine months ended December 31, 2025.

The transcript is made available on the company's website, as stated in the filing under Regulation 30(6) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The filing itself contains no financial figures or management commentary; the transcript content is not included in the pages provided.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Feb 2026presentation
Results
Caplin Point Laboratories Limited has informed the Exchange about Investor Presentation
AI summary

Caplin Point Laboratories' board approved unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025, on February 5, 2026, with a press release and investor presentation enclosed.

Standalone revenue from operations for Q3 FY26 was Rs 189.22 crores (vs Rs 185.23 crores a year earlier); standalone net profit was Rs 87.28 crores (vs Rs 74.71 crores); basic EPS was Rs 11.49.

Nine-month standalone revenue from operations was Rs 546.97 crores (vs Rs 578.80 crores) and net profit was Rs 275.79 crores (vs Rs 252.99 crores).

Standalone other income for Q3 was Rs 31.73 crores, and the company noted a Rs 0.84 crore increase in employee benefit obligations from the new Labour Codes, recognised in the quarter.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Feb 2026board outcome
Results
Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
AI summary

Caplin Point Laboratories filed the outcome of its February 5, 2026 board meeting, which approved unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025, with a limited review report and press release and investor presentation enclosed.

Standalone revenue from operations for Q3 FY26 (quarter ended December 31, 2025) was Rs 189.22 crores, against Rs 185.23 crores a year earlier and Rs 175.18 crores in the previous quarter.

Standalone net profit for the quarter was Rs 87.28 crores, against Rs 74.71 crores a year earlier; basic EPS was Rs 11.49 against Rs 9.83.

For the nine months ended December 31, 2025, standalone revenue from operations was Rs 546.97 crores (against Rs 578.80 crores) and net profit was Rs 275.79 crores (against Rs 252.99 crores).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Nov 2025transcriptCaplin Point Laboratories Limited has informed the Exchange about Transcript
AI summary

Caplin Point Laboratories Limited filed the transcript of its Q2 and H1 FY2025-26 earnings call, held on November 6, 2025, under Regulation 30(6) of the SEBI Listing Regulations.

The transcript is available on the company's website rather than attached to this letter.

The filing covers financial performance for the quarter and half-year ended September 30, 2025.

The letter itself contains no financial figures or management commentary.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Nov 2025board outcome
Management change, Results
Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Caplin Point Laboratories filed the outcome of its board meeting held on 5 November 2025, which approved unaudited standalone and consolidated results for the quarter and half year ended 30 September 2025.

Standalone revenue from operations was Rs 175.18 crores for the quarter and Rs 357.75 crores for the half year; standalone net profit was Rs 102.59 crores for the quarter and Rs 188.48 crores for the half year.

The board appointed Mr. Ashok Partheeban and Mr. Vivek Partheeban as Additional Directors and Vice-Chairmen, effective 5 November 2025, subject to shareholder approval.

Mr. Vivek Partheeban relinquished his position of Chief Operating Officer with immediate effect.

The board appointed Dr. K C John as Additional Director (Non-Executive Independent) for five years from 5 November 2025, subject to shareholder approval.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Aug 2025transcriptCaplin Point Laboratories Limited has informed the Exchange about Transcript
AI summary

Caplin Point Laboratories Limited filed a transcript of its Q1 FY2025-26 earnings call held on August 7, 2025, covering the quarter ended June 30, 2025.

The transcript is available on the company's website at the link given in the filing.

The filing itself does not state any financial figures or management commentary.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Aug 2025board outcome
Dividend / buy-back, Results
Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AI summary

Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a press release and investor presentation enclosed.

Standalone revenue from operations for Q1 FY26 was Rs 182.57 crore, against Rs 185.64 crore in the year-ago quarter; total income was Rs 214.60 crore and net profit was Rs 85.89 crore (Rs 72.54 crore a year earlier).

Basic EPS for the quarter was Rs 11.30 (not annualised), against Rs 9.55 a year earlier.

Board recommended a final dividend of Rs 3 per equity share (150%) of Rs 2 face value for FY2024-25, payable on or before October 21, 2025, subject to AGM approval; the record date will be communicated separately.

Board approved convening the 34th Annual General Meeting on September 22, 2025 via video conferencing or other audio-visual means.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Aug 2025dividend
Dividend / buy-back, Results
Caplin Point Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on August 07, 2025, recommended Final Dividend of Rs. 3 per equity share.
AI summary

Board approved a final dividend of Rs 3 (150%) per equity share of Rs 2 each for FY ended March 31, 2025, payable on or before October 21, 2025, subject to AGM approval; an interim dividend of Rs 3 per share was paid on June 9, 2025.

Board approved unaudited standalone and consolidated results for the quarter ended June 30, 2025, with standalone revenue from operations of Rs 182.57 crore, total income of Rs 214.60 crore and net profit of Rs 85.89 crore (vs Rs 72.54 crore in the year-ago quarter).

Board approved the 34th Annual General Meeting to be held on September 22, 2025 via video conferencing or other audio-visual means; the record date for the final dividend is to be communicated separately.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 May 2025transcriptCaplin Point Laboratories Limited has informed the Exchange about Transcript
AI summary

Caplin Point Laboratories Limited filed the transcript of its Q4 FY2024-25 earnings call, held on Thursday, May 15, 2025.

The call covered financial performance for the quarter and year ended March 31, 2025.

The transcript is available on the company's website, as stated in the filing.

The filing is made under Regulation 30(6) of the SEBI (LODR) Regulations, 2015, and follows the company's letter dated May 07, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
15 May 2025board outcome
Dividend / buy-back, Guidance, Legal, Results
Caplin Point Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.
AI summary

Board outcome for the year ended March 31, 2025: interim dividend of INR 3.00 per equity share (150%) on face value INR 2, with May 30, 2025 fixed as record date.

Audited standalone and consolidated FY25 results approved: consolidated total revenue INR 2,033.9 crore (up 15.5% YoY), PAT INR 541.1 crore (up 17.3%), basic EPS INR 70.57; statutory auditor issued unmodified opinion.

Board appointed M/s M Alagar & Associates as Secretarial Auditors for five years FY2025-26 to FY2029-30, subject to shareholder approval at the AGM.

Press release states management (Chairman C.C. Paarthipan) is delighted with top and bottom line growth and expects the US front-end (Caplin Steriles USA) to drive strong growth over the next few years; company expects 10-12 ANDA approvals in FY26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Feb 2025transcriptCaplin Point Laboratories Limited has informed the Exchange about Transcript
AI summary

Caplin Point Laboratories Limited filed the transcript of its Q3 FY2024-25 earnings call, held on February 07, 2025, covering the quarter and nine months ended December 31, 2024.

The transcript is available on the company's website at the link given in the filing.

The filing is a cover letter under Regulation 30(6) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015; the pages provided do not include the call content or any figures.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Feb 2025results
Results
Integrated Filing (Financial) for Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024
AI summary

Caplin Point Laboratories filed its integrated filing with unaudited standalone financial results for the quarter and nine months ended December 31, 2024, approved by the Board and reviewed by Brahmayya & Co.

Standalone net profit for the quarter ended December 31, 2024 was Rs 74.71 crore, against Rs 55.45 crore in the corresponding quarter a year earlier; nine-month net profit was Rs 252.99 crore, against Rs 213.82 crore.

Revenue from operations for the quarter was reported as Rs 214.06 crore (OCR of the table is partly unclear; the nine-month figure appears as Rs 578.80 crore).

Basic EPS for the quarter was Rs 9.83 (not annualised) against Rs 3.92 in the year-earlier quarter as printed in the OCR text; the filing states no deviation of proceeds, no default on loans or debt securities.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Feb 2025results
Results
Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
AI summary

Caplin Point Laboratories filed its outcome of board meeting held February 7, 2025, approving unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2024, with a limited review report and press release and investor presentation enclosed.

Standalone revenue from operations for the quarter ended December 31, 2024 was Rs 185.23 crores (OCR reading; comparable quarter figures in the table are partly garbled), and standalone net profit for the quarter was Rs 74.71 crores.

Standalone net profit for the nine months ended December 31, 2024 was Rs 252.99 crores, against Rs 213.82 crores for the nine months ended December 31, 2023.

Basic EPS for the quarter was Rs 4.92 (OCR text partly unclear); the company has 7,60,11,696 equity shares outstanding as at December 31, 2024.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Feb 2025board outcome
Results
Caplin Point Laboratories Limited has informed the Exchange regarding Board meeting held on February 07, 2025.
AI summary

Board outcome filed on February 7, 2025 approving unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with a Limited Review Report from the statutory auditors.

Standalone revenue from operations for the quarter ended December 31, 2024 was Rs 185.23 crore (OCR text partly garbled; comparable figures for the quarter ended December 31, 2023 and nine months ended December 31, 2024 were also reported).

Standalone net profit for the quarter ended December 31, 2024 was Rs 74.71 crore, against Rs 55.45 crore for the quarter ended December 31, 2023 (as read from the statement).

Standalone diluted EPS for the quarter was Rs 9.77 (not annualised), per the statement; the nine-month standalone net profit was Rs 253.11 crore.

The filing enclosed a press release and investor presentation, which were not included in the pages provided, so management commentary could not be assessed.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in